ferric citrate (fe-rik si-trate) Auryxia

 Indications

Control of serum phosphorous in chronic renal failure

patients on dialysis.

Action

Binds phosphorous and precipitates it as ferric phosphate.

Therapeutic Effects: Maintenance of normal

phosphorous levels.

Pharmacokinetics

Absorption: Some absorption follows oral administration

and may lead to iron overload.

Distribution: Unknown.

Metabolism and Excretion: Following binding,

precipitated ferric phosphate is excreted in stool.

Half-life: Unknown.

TIME/ACTION PROFILE (lowering of serum

phosphorous)

ROUTE ONSET PEAK DURATION

PO within 1 wk unknown unknown

Contraindications/Precautions

Contraindicated in: Iron overload syndromes including

hemochromatosis.

Use Cautiously in: GI bleeding/inflammation; OB:

Use cautiously during pregnancy (consider effects on

vitamins/nutrient and potential iron overload); Lactation:

Consider possible iron transport into milk; Pedi:

Safety and effectiveness not established.

Adverse Reactions/Side Effects

GI: diarrhea, discolored feces, nausea, constipation,

vomiting. Misc: iron overload.

Interactions

Drug-Drug: Binds andpabsorption of doxycycline

(should be given 1 hr prior to ferric citrate). Binds

andpabsorption of ciprofloxacin (should be given

2 hr prior to or after ferric citrate).

Route/Dosage

PO (Adults): 2 tablets (2 g ferric citrate) 3 times daily.

Adjust by 1–2 tablets/day at weekly (or longer) intervals

to attain target phosphorous levels.

Availability (generic available)

Tablets: 1 g (contains 210 mg ferric iron).